Cargando…

A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt(IV) Complexes under Physiological Conditions

Due to their high kinetic inertness and consequently reduced side reactions with biomolecules, Pt(IV) complexes are considered to define the future of anticancer platinum drugs. The aqueous stability of a series of biscarboxylato Pt(IV) complexes was studied under physiologically relevant conditions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kastner, Alexander, Poetsch, Isabella, Mayr, Josef, Burda, Jaroslav V., Roller, Alexander, Heffeter, Petra, Keppler, Bernhard K., Kowol, Christian R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766845/ https://www.ncbi.nlm.nih.gov/pubmed/30870571 http://dx.doi.org/10.1002/anie.201900682

Ejemplares similares

Improving the Stability of Maleimide–Thiol Conjugation for Drug Targeting
por: Lahnsteiner, Marianne, et al.
Publicado: (2020)

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
por: Mendrina, Theresa, et al.
Publicado: (2023)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)
por: Frensemeier, L. M., et al.
Publicado: (2018)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

EGFR-targeting peptide-coupled platinum(IV) complexes
por: Mayr, Josef, et al.
Publicado: (2017)

Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney
por: Legin, A. A., et al.
Publicado: (2016)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021)

Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes
por: Mathuber, Marlene, et al.
Publicado: (2021)

The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
por: Berasaluce, Iker, et al.
Publicado: (2019)

Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux
por: Bormio Nunes, Julia H., et al.
Publicado: (2020)

Another step toward DNA selective targeting: Ni(II) and Cu(II) complexes of a Schiff base ligand able to bind gene promoter G-quadruplexes
por: Terenzi, Alessio, et al.
Publicado: (2016)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

Consumption and Dogma
Publicado: (1910)

Challenging the dogma
por: Brand-Miller, Jennie
Publicado: (2020)

Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin
por: Nosova, Yulia N., et al.
Publicado: (2017)

Subluxation: dogma or science?
por: Keating, Joseph C, et al.
Publicado: (2005)

Dog eat dogma
por: A Petsko, Gregory
Publicado: (2000)

Central dogma alchemy
por: Bandyra, Katarzyna, et al.
Publicado: (2015)

Challenges to the Common Dogma
por: Yu, Jun
Publicado: (2012)

Dogmas and Fashions in Practice
por: Cartledge, E. C.
Publicado: (1905)

The tube, the pancreatoduodenectomy—and the dogma
por: Lassen, Kristoffer
Publicado: (2021)

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
por: Pelivan, Karla, et al.
Publicado: (2018)

Doubt, a history /
por: Hecht, Jennifer Michael, 1965-
Publicado: (2004)

Doubting darkness
Publicado: (2017)

In Faith and In Doubt
por: McGowan, Dale
Publicado: (2014)

Challenging the dogma of simultaneous resection of bladder tumor and benign prostate
por: Tsivian, Matvey, et al.
Publicado: (2018)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs
por: Mathuber, Marlene, et al.
Publicado: (2020)

El dogma de Cristo
por: Fromm, Erich, 1900-1980
Publicado: (1970)

Modern dogma and the rhetoric of assent
por: Booth, Wayne C.
Publicado: (1974)

El derecho como dogma /
por: Hernández Marín, Rafael
Publicado: (1984)

El dogma de Cristo
por: Fromm, Erich, 1900-1980
Publicado: (1992)

Introduction: challenging established dogma
por: Santen, Richard J
Publicado: (2007)

Dogma in Classifying Dengue Disease
por: Farrar, Jeremy J., et al.
Publicado: (2013)

Theoretical Investigations and Density Functional Theory Based Quantitative Structure–Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes
por: Varbanov, Hristo P., et al.
Publicado: (2012)

Hawking doubts LHC
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_32gkd4tlodjnc2se41df781qsq